Almac Successfully Completes Knowledge Transfer Partnership with Queens University with Highest Accolade
January 21, 2013
Almac is pleased to announce the successful completion of the Knowledge Transfer Partnership (KTP) with Queens University, Belfast to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for its biocatalysis business. The project was awarded the highest grade of “Outstanding” by the KTP Grading Panel for it’s achievement in meeting KTP’s objectives.
The overall partnership aim was to allow technology transfer of fermentation and molecular / microbiology expertise from Queens University to Almac. Almac met the specific partnership objectives by not only sharing a program of work with academics at Queens, but also attending training courses organised through University College London and embedding key learning back into the company.
The resulting success of this collaboration is that Almac can now deliver a fully integrated fermentation, optimisation and bio-product service to its customers. Since completion of the KTP, Almac have successfully scaled fermentation and bio-oxidation reactions to thousands of litres.
Dr Tom Moody, Head of Biocatalysis and Radiolabelling Services, is understandably delighted with the results of this partnership: “To receive the highest grade of Outstanding is a huge achievement for Almac, and testament to the commitment of the team involved. Not only have we further strengthened our long-standing relationship with Queens University, but we have also increased our service offering within the biocatalysis field to our clients, thus allowing us to compete in an area which was previously beyond our reach.”
This achievement follows from an extremely successful year for Almac’s biocatalysis service offering. 2012 saw the launch of its metabolite synthesis services, winning a Belfast Telegraph Award in Excellence in Technology, and announcing an industry-leading biocatalysis collaboration with DSM Pharmaceutical Products.
Notes to Editors
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.